



The American College of  
Obstetricians and Gynecologists  
WOMEN'S HEALTH CARE PHYSICIANS

## Physician Script Concerning HPV Vaccination

Human papillomavirus (HPV) vaccination is recommended for all female and male patients aged 9–26 years with a target age for vaccination at age 11 years to 12 years. Two HPV vaccines are currently available. These vaccines are bivalent, which is approved for use in girls and protects against HPV types 16 and 18 (the most common cause of cervical cancer) and quadrivalent, which is approved for use in boys and girls and protects against HPV types 16 and 18 as well as HPV types 6 and 11 (associated with genital warts).

The vaccines are highly effective and produce a robust immune response and persistent immune memory. Studies of both HPV vaccines have shown that among participants who had not been exposed to the vaccine genotypes, the vaccines are nearly 100% effective in preventing cervical intraepithelial neoplasia (CIN) 2,3 related to the HPV types 16 and 18. The quadrivalent vaccine has also shown to be nearly 100% effective in preventing vaginal and vulvar intraepithelial neoplasia and genital warts caused by HPV genotypes 6 and 11. These vaccines can prevent significant amounts of serious health problems when given to a patient who has not been exposed to HPV because 70% of cervical cancer is associated with HPV types 16 and 18 and 90% of genital warts are associated with HPV types 6 and 11 (included in the quadrivalent vaccine). In the United States, cervical cancer is the seventh leading cause of mortality among women, and there are approximately 1 million cases of precancerous cells or lesions and 360,000 cases of genital warts each year.

The vaccines are not recommended during pregnancy. If inadvertently administered during pregnancy, HPV vaccination has not shown to be harmful. It is safe to administer postpartum, during breastfeeding, and to family members. Pregnancy testing is not required prior to vaccination.

It is required by law for you to give your patients a Vaccine Information Statement upon receiving an immunization. Vaccine Information Statement forms can be found in multiple languages at [www.immunize.org/vis/](http://www.immunize.org/vis/).

Multiple studies show that the most effective way to increase your patients' vaccination acceptance rate is for you to directly recommend and provide the vaccine. Talk to your patients or their parents about HPV vaccination today. Here is a script for your consideration when talking to a parent with a child in the target age range or age-eligible females:

**“I strongly recommend human papillomavirus vaccination to all of my patients who are 9- to 26-years-old. I also recommend it to my patients who have children or grandchildren in that age range. Vaccination reduces the chances of cervical, vaginal, vulvar, anal, and oral cancer in females and penile, anal, and oral cancer in males. It also reduces the number of abnormal Pap test results, which saves women from having examinations they do not need. Human papillomavirus is extremely common—80% of people are exposed to the virus during their lifetime. Even having only one lifetime partner can expose you to the virus and put you at risk. This is why prevention is so important. Both HPV vaccines are safe and effective. I recommend vaccination at age 11 years to 12 years. If that doesn't happen, I recommend 'catch-up' vaccination for up to age 26 years.”**

### RESOURCES

The American College of Obstetricians and Gynecologists  
Human papillomavirus vaccination. Committee Opinion No. 588. American College of Obstetricians and Gynecologists. *Obstet Gynecol* 2014;123:712–8.

Center for Disease Control and Prevention  
[cdc.gov/vaccinesafety/vaccines/HPV/index.html](http://cdc.gov/vaccinesafety/vaccines/HPV/index.html)



## Coding Information on HPV Immunization

### CPT Codes for Vaccine Administration

Code	Method	Route of Administration	Type of Service	Reporting Rules
90471	Injection	Percutaneous, intradermal, subcutaneous, or intramuscular	Primary	Report only one primary vaccine administration per encounter.
+90472	Injection	Percutaneous, intradermal, subcutaneous, or intramuscular	Additional	Report for secondary or subsequent vaccine administration. Report only with code 90460, 90471, or 90473.
90460	Any route	Percutaneous, intradermal, subcutaneous, or intramuscular	Primary	Report only one primary vaccine administration per day. Report for administration of first vaccine if more than one was provided. Physician or other Qualified Health Professional also provides counseling. Patient is 18 years of age or younger.
90461	Any route	Percutaneous, intradermal, subcutaneous, or intramuscular	Additional	Report for secondary or subsequent vaccine administration. Physician or other Qualified Health Professional also provides counseling. Patient is 18 years of age or younger.

### HPV Vaccines Administered to Adolescents and Adults

Vaccine	Code for Vaccine Product	CPT Administration Code
HPV types 6, 11, 16, 18 (quadrivalent), 3-dose schedule, intramuscular	90649	90460-90472
HPV types 16, 18 (bivalent), 3-dose schedule, intramuscular	90650	90460-90472

*This information is provided by the American College of Obstetricians and Gynecologists for educational purposes only. It is not intended to represent the only, or necessarily the best, coding format or method for the situations discussed, but rather as an approach, view, statement, or opinion that may be helpful to persons responsible for diagnosis and procedure coding. The statements made in this document should not be construed as the American College of Obstetricians and Gynecologists' policy or procedure or as standards of care. The American College of Obstetricians and Gynecologists makes no representations or warranties, expressed or implied, regarding the accuracy of the information contained in this document and disclaims any liability or responsibility for any consequences resulting from or otherwise related to any use of, or reliance on, this information.*

For more information, please visit the Coding section on the Immunization for Women web page, [www.immunizationforwomen.org/practice\\_management/coding](http://www.immunizationforwomen.org/practice_management/coding).